CBS This Morning Features Pfizer’s Phase 3 COVID-19 Vaccine Trial
September 9, 2020
Clinical study supported by Almac Clinical Services
Almac Group is proud to be continuing our partnerships with a variety of global pharmaceutical, biotech and research institutions to support over 80 separate crucial research projects and having further discussions with clients on how we can support an additional 50 programmes.
Almac Clinical Services is currently supporting a clinical study which has been featured as part of CBS This Morning’s Coronavirus “The race to respond” series. On 21st August “The race for a vaccine” feature focused on Pfizer and BioNTech’s vaccine trial, now in phase 3, where CBS’s Chief Medical Advisor, Dr John Lapook, reported on the progress of the clinical trial programme and the incredible milestones achieved thus far.
Almac is currently performing secondary labelling, storage, distribution, depots, TempEZ™ life cycle management, adjudication and pharmacist services for this product. The video footage used for the CBS report shows the use of Almac’s bespoke temperature controlled shipping solution, the Almac Pod™, which is used to transport the vaccine in the required frozen condition and safeguards the product against temperature changes throughout transit. This ensures the patient receives a stable, fit-for-purpose drug which has not been compromised at any stage.
Dr Robert Dunlop, Managing Director, Clinical Services commented: “We are proud to be playing our part in the fight against COVID-19 and the inclusion of our innovative shipping solution, the Almac Pod, in this CBS report for the current Pfizer and BioNTech’s phase 3 study is really poignant as it acts as a reminder of how the work we do on a daily basis directly contributes to the well-being of patients right across the world. We wish Pfizer and BioNTech, and indeed all our partners, every success with finding an effective treatment or vaccine to help end this pandemic.”